Targeting Inflammation in Atherosclerosis
Published: 08 April 2022
As we continue to move beyond lipid lowering treatment options and explore novel possibilities targeting residual inflammatory risk, there is a substantial unmet educational need to support cardiologists. Inflammation plays a significant role during atherosclerosis and several lines of evidence suggest that inhibiting the inflammatory cytokines along the IL-6 axis reduces adverse events in CAD.
This independent medical educational programme aims to increase knowledge on the causal relationship between inflammation and cardiovascular disease (CVD) – an underappreciated therapeutic target for the prevention of CV progression and events.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change
- Discuss the complex relationship between inflammation and the development of ASCVD and renal impairment
- Summarise therapeutic targets of inflammation along the IL-6 axis
- Recall how hsCRP can be used as a biomarker for inflammation
- Recall the latest clinical trial and pre-clinical data assessing anti-inflammatory strategies to overcome atherosclerosis and how this relates to current guidance
- Rationalise the mode of action behind the use of monoclonal antibody therapy along the IL-6–CRP axis
- Contrast the use of novel treatments targeting inflammation in atherosclerosis with existing therapies that have shown clinical benefit
- General Cardiologists
More from this programme
Current guidelines and clinical data
Therapeutic targets and mode of action
Unmet clinical needs in atherosclerosis and chronic kidney disease
Inflammation and atherosclerosis
Inflammatory signalling in atherosclerosis and CKD
Juan Carlos Kaski
Professor of Cardiovascular Science
Juan Carlos Kaski is Professor of Cardiovascular Science (Emeritus) at the Molecular and Clinical Sciences Research Institute, St Gorge’s, University of London, and Hon. Consultant Cardiologist at St George’s Hospital and the Royal Brompton Hospital in London, UK. He is Doctor Honoris Causa of several universities worldwide, a past-President of the International Society of Cardiovascular Pharmacotherapy and Fellow of over 30 scientific societies worldwide. JC Kaski has received numerous national and international awards for his research work and both his clinical and educational activities. Professor Kaski is Chairman-elect, European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Editor-in-Chief of the European Cardiology Review Journal, Deputy Editor of the European Heart Journal, Co-Editor of the ESC Handbook on Cardiovascular Pharmacotherapy and editorial board member of JACC and over 20 other scientific journals. Prof Kaski’s research areas include…
Dr Peter Libby is the Mallinckrodt Professor of Medicine at Harvard Medical School and is the previous Chief of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston, Massachusetts.
His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis.